Heidelberg Pharma AG and Magenta Therapeutics Inc. signed an exclusive agreement to develop therapies that can be used to improve bone marrow transplants.
Under the multitarget research agreement, the companies will work together to develop antibody drug conjugates, a new type of cancer treatment, to support Magenta's work in the field of bone marrow transplant medicine.
Germany-based Heidelberg Pharma will receive up to $334 million in option fees, clinical development, regulatory and sales-related milestone payments, if Magenta exercises all target options and all milestones are met, the companies said.
Magenta's stem cell platform with proprietary antibodies will be combined with Heidelberg Pharma's antibody targeted amanitin conjugates platform. The deal will cover up to four exclusive targets.
Heidelberg Pharma will grant Cambridge, Mass.-based Magenta access to its amanitin toxin-linker platform technology. Magenta can opt to hold an exclusive target-specific license to develop and sell the product candidates that result from the partnership.
